CytomX Therapeutics CTMX, a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on ...

Bio-Techne Corporation TECH recently announced Asuragen’s — a Bio-Techne brand —partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

Here's what Dr Sinicrope said to see a healthcare provider if you experience any of the following symptoms of early-onset ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

Shah and colleagues take advantage of the presence of maternal and somatic ribosomes in zebrafish and confirm their differential expression during development. The authors convincingly show that ...

Non-coding RNAs and oxidative stress work together in various stages of cancer progression, including cancer cell growth and reproduction, cancer ...

(NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM ...